Exagen Future Growth

Future criteria checks 1/6

We currently don't have sufficient analyst coverage to forecast growth and revenue for Exagen.

Key information

11.4%

Earnings growth rate

17.5%

EPS growth rate

Biotechs earnings growth48.9%
Revenue growth rate17.4%
Future return on equityn/a
Analyst coverage

Good

Last updated22 May 2023

Recent future growth updates

Recent updates

Earnings and Revenue Growth Forecasts

DB:E08A - Analysts future estimates and past financials data (USD Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/202571-26-20-184
12/31/202456-29-26-256
12/31/202346-32-30-296
3/31/202041-31-11-11N/A
12/31/201940-30-10-10N/A
9/30/201940-31-8-8N/A
6/30/201938-18-9-8N/A
3/31/201935-18-8-8N/A
12/31/201832-18-9-9N/A
12/31/201727-33-12-11N/A
12/31/201518-21N/A-12N/A
9/30/201518-21N/A-11N/A
6/30/201517-23N/A-10N/A
3/31/201515-17N/A-10N/A
12/31/201412-17N/A-11N/A
9/30/20149-23N/A-11N/A
6/30/20146-21N/A-10N/A
3/31/20144-19N/A-8N/A
12/31/20133-18N/A-7N/A
12/31/201210N/A-7N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: E08A is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: E08A is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: E08A is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: E08A's revenue (17.4% per year) is forecast to grow faster than the German market (4.3% per year).

High Growth Revenue: E08A's revenue (17.4% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if E08A's Return on Equity is forecast to be high in 3 years time


Discover growth companies